Diabetes: NAFDAC Disclaims AAU’s Herbal Remedy
The National Agency for Food and Drug Administration and Control (NAFDAC), yesterday, disowned claims that a listed local herbal medicine, Glucozil, produced by Ambrose Alli University, Ekpoma, Edo State, was approved by the agency for the treatment and cure of Diabetes Mellitus and capable of treating Benign prostatic hyperplasia (Prostate enlargement) together with some anti-inflammatory properties.
Director General of NAFDAC, Prof. Christianah , in a statement, yesterday, said that in a publication on August 24, Glucozil was claimed to have been scientifically tested with safety established in both humans and animals.
Read Also:
Read Also: NAFDAC Approves Herbal Medicine for Diabetes
Adeyeye said: “The Agency listed Glucozil capsule on November 10, 2020, for the management of high blood sugar (as captured on the approved label and Listing Certificate issued to the applicant), which was valid till November 9, 2022. Therefore the herbal medicine certificate has expired.”
As specified in the Herbal Medicine & Related Products Labelling Regulations 2021, this listing was subject to inclusion of the mandatory disclaimer.”
Adeyeye said that these claims have not been evaluated by NAFDAC on the product label, stressing that this is the regular disclaimer that is used and required for other listed herbal products, which have not undergone clinical trials that the agency deemed satisfactory.
